Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer
(2016) In Drug Discovery Today 21(7). p.8-1181- Abstract
Estrogen receptor (ER)-positive breast cancer represents the majority (∼70%) of all breast malignancies. In this subgroup of breast cancers, endocrine therapies are effective both in the adjuvant and recurrent settings, although resistance remains a major issue. Several high-throughput approaches have been used to elucidate mechanisms of resistance and to derive potential predictive markers or alternative therapies. In this review, we cover the state-of-the-art of endocrine-resistance biomarker discovery with regard to the latest technological developments, and discuss current opportunities and restrictions for their implementation into a clinical setting.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/d7c8b01e-0eb3-49ac-a1e2-16ee7272dbc9
- author
- De Marchi, Tommaso LU ; Foekens, John A. ; Umar, Arzu and Martens, John W. M.
- publishing date
- 2016-07
- type
- Contribution to journal
- publication status
- published
- in
- Drug Discovery Today
- volume
- 21
- issue
- 7
- pages
- 8 pages
- publisher
- Elsevier
- external identifiers
-
- pmid:27233379
- scopus:84969921763
- ISSN
- 1878-5832
- DOI
- 10.1016/j.drudis.2016.05.012
- language
- English
- LU publication?
- no
- id
- d7c8b01e-0eb3-49ac-a1e2-16ee7272dbc9
- date added to LUP
- 2017-06-27 14:33:48
- date last changed
- 2024-06-09 19:02:21
@article{d7c8b01e-0eb3-49ac-a1e2-16ee7272dbc9,
abstract = {{<p>Estrogen receptor (ER)-positive breast cancer represents the majority (∼70%) of all breast malignancies. In this subgroup of breast cancers, endocrine therapies are effective both in the adjuvant and recurrent settings, although resistance remains a major issue. Several high-throughput approaches have been used to elucidate mechanisms of resistance and to derive potential predictive markers or alternative therapies. In this review, we cover the state-of-the-art of endocrine-resistance biomarker discovery with regard to the latest technological developments, and discuss current opportunities and restrictions for their implementation into a clinical setting.</p>}},
author = {{De Marchi, Tommaso and Foekens, John A. and Umar, Arzu and Martens, John W. M.}},
issn = {{1878-5832}},
language = {{eng}},
number = {{7}},
pages = {{8--1181}},
publisher = {{Elsevier}},
series = {{Drug Discovery Today}},
title = {{Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer}},
url = {{http://dx.doi.org/10.1016/j.drudis.2016.05.012}},
doi = {{10.1016/j.drudis.2016.05.012}},
volume = {{21}},
year = {{2016}},
}